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Objectives: Genetic markers in the genes encoding ankyrin 3 (ANK3)
and the a-calcium channel subunit (CACNA1C) are associated with
bipolar disorder (BP). The associated variants in the CACNA1C gene
are mainly within intron 3 of the gene. ANK3 BP-associated variants are
in two distinct clusters at the ends of the gene, indicating disease allele
heterogeneity.
Methods: In order to screen both coding and non-coding regions to
identify potential aetiological variants, we used whole-genome
sequencing in 99 BP cases. Variants with markedly diﬀerent allele
frequencies in the BP samples and the 1,000 genomes project European
data were genotyped in 1,510 BP cases and 1,095 controls.
Results: We found that the CACNA1C intron 3 variant, rs79398153,
potentially aﬀecting an ENCyclopedia of DNA Elements (ENCODE)-
deﬁned region, showed an association with BP (p = 0.015). We also
found the ANK3 BP-associated variant rs139972937, responsible for an
asparagine to serine change (p = 0.042). However, a previous study had
not found support for an association between rs139972937 and BP. The
variants at ANK3 and CACNA1C previously known to be associated
with BP were not in linkage disequilibrium with either of the two
variants that we identiﬁed and these are therefore independent of the
previous haplotypes implicated by genome-wide association.
Conclusions: Sequencing in additional BP samples is needed to ﬁnd the
molecular pathology that explains the previous association ﬁndings. If
changes similar to those we have found can be shown to have an eﬀect
on the expression and function of ANK3 and CACNA1C, they might
help to explain the so-called ‘missing heritability’ of BP.
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Bipolar disorder (BP) is a common disease with a
worldwide average population prevalence of 1.4%,
which rises to 2.4% if bipolar spectrum disorders
are included (1). Twin and family studies indicate
that BP is genetically related to some types of uni-
polar aﬀective disorder (2). The genetic heritability
of BP is thought to be between 79% and 93%
(3–6), with a ten-fold increase in risk to the
relatives of probands with BP (7). Many linkage
studies of speciﬁc chromosomal regions and whole
genomes in multiply aﬀected families support the
presence of locus heterogeneity, with multiple sus-
ceptibility loci (8–10). About half of the segrega-
tion analyses of systematically ascertained families
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imply that BP has an autosomal dominant mode
of inheritance (11). Other models have favoured a
single major locus with a polygenic multifactorial
background and pure polygenic transmission.
Linkage and linkage disequilibrium (LD) analyses
demonstrate locus heterogeneity (12, 13). Genome-
wide association studies (GWAS), meta-analyses,
and replication studies focusing on BP have been
carried out on combined cohort sizes of up to
7,481 cases and 9,250 controls (14–17). These and
other single-locus case–control association studies
have repeatedly implicated the L-type calcium
channel a1C subunit (CACNA1C) and ankyrin 3
(ANK3) genes in BP. The strongest allelic associa-
tion signal in CACNA1C is localized entirely
within intron 3 of the gene with the single nucleo-
tide polymorphisms (SNPs) rs1006737 (p = 7.0 9
108) (14, 18, 19), rs4765913 (p = 1.52 9 108)
(14), rs4765914 (p = 1.52 9 108) (20), and rs1024
582 (p = 1.7 9 107) (17, 21). GWAS results
across ﬁve diﬀerent psychiatric illnesses further
implicate rs1024582 in susceptibility to both BP
and schizophrenia, assuming that there has not
been substantial misdiagnosis, especially where
schizoaﬀective BP cases are included in the schizo-
phrenia group (20). Intron 3 of CACNA1C con-
tains a chromosomal region with high levels of
LD, strong mammalian conservation, and multiple
sites designated by the ENCyclopedia of DNA Ele-
ments (ENCODE) project as being able to aﬀect
gene expression. Studies show that that the pres-
ence of the rs1006737 CACNA1C BP risk variant
may have an impact on certain brain activities.
One study showed that the rs1006737 risk variant
in healthy males is associated with lower extraver-
sion, trait anxiety, paranoid ideation, and higher
harm avoidance (22). The rs1006737 risk variant
has been associated with increased amygdala func-
tioning observed by magnetic resonance imaging
during emotional processing; the enhancement of
activation leads to impaired facial emotion recog-
nition in BP patients (20, 23–26). There has been
conﬂicting evidence as to whether the presence of
the CACNA1C variant results in brain volumetric
alteration. Some reports state that this SNP has
been associated with brainstem alterations,
increased grey matter density, as well as a cortical
volume increase (27–29). A conﬂicting study did
not report any association between this SNP and
brain volumetric alterations (30). Mutations/vari-
ants located in intronic regions can also aﬀect the
stability of RNA and protein expression, and can
have a strong eﬀect on the transcriptional regula-
tion of the gene.
In ANK3, the strongest evidence for allelic asso-
ciation comes from SNPs rs10994338 (p = 1.20 9
107) (31), rs4948418 (p = 8.93 9 109) (15), rs
10994336 (p = 9.1 9 109) (14, 26, 32–34), rs1099
4397 (p = 7.1 9 109) (17) at the 50 end, and the
SNP rs9804190 (p = 1.20 9 104) (17, 26, 35) at
the 30 end of the longest isoform (NM_001204403)
of the gene. These regions are over 340 kb apart
and appear to be independently associated with
BP, with no signiﬁcant interactions between SNPs
from the two regions (32). However, the existing
data on ANK3 show that only low-frequency aetio-
logical base-pair (bp) changes are present with an
odds ratio less than 1.35 for BP (17). The SNP
associations are not replicated in every study (36–
39); however, the ANK3 association has been
reported in several diﬀerent ancestral populations
(36, 40–42). Several novel, rare potential aetiologi-
cal bp changes have been identiﬁed by us through
sequencing the gene in our samples. These were
selected for having haplotypes associated with BP
(43). Doyle et al. (44) sequenced the 8 kb brain-
expressed exon 48 of ANK3 but could not ﬁnd
potential aetiological bp changes that were associ-
ated with BP. This exon is of recent evolutionary
history, and variation in the exon appears to be
tolerated. Sequencing analysis of ANK3 demon-
strated the impact of heterogeneity on replication
of allelic associations, even within well-deﬁned
ancestral populations (43). mRNA analysis has
detected diﬀerential regulation of distinct ANK3
transcription start sites and coupling of speciﬁc 50
ends with 30 mRNA splicing events, suggesting
that brain-speciﬁc cis-regulatory transcriptional
changes might be relevant to BP molecular pathol-
ogy (45). Gene network analysis and test of epista-
sis have found further support for an association
of ANK3 with BP (46, 47). The genetic variants
associated with disease have no known biological
function. However, one study showed that the
presence of the rs10994336 BP risk variant in
healthy males might predict lower novelty seeking,
lower behavioural activation scores, and high star-
tle reactivity (22). In healthy volunteers, rs10994
336 may be associated with reduced white matter
integrity in the anterior limb of the internal cap-
sule, as well as with altered set-shifting and deci-
sion-making (48). These ﬁndings may be consistent
with previous diﬀusion tensor imaging studies in
patients with BP (49–54) and core phenotypes of
BP (55–58). Lithium has been shown to alter Ank3
mRNA levels in the mouse brain (59), and lithium
and sodium valproate have been shown to change
Ank3 protein amounts in rat neuronal dendritic
spines (60). In another animal model, RNA inter-
ference of Ank3 in the hippocampus dentate gyrus
induced a reduction of anxiety-related behaviours
and increased activity during the light phase, which
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were attenuated by chronic treatment with the
mood stabilizer, lithium. Similar behavioural alter-
ations of reduced anxiety and increased motivation
for reward were also exhibited by Ank3+/ hetero-
zygous mice compared with wild-type Ank3+/+
mice (61).
Given the typical natural history of BP, which
consists of episodes of both mania and depression
with complete recovery very often between epi-
sodes, it can be argued that genetic susceptibility
will involve aetiological bp changes inﬂuencing the
control of gene expression and mRNA translation
rather than mutations creating structural protein
abnormalities. Therefore, we chose whole-genome
sequencing (WGS) rather than exome sequencing
in order to be able to investigate intronic and non-
coding control regions of susceptibility genes along
with the exonic coding regions.
Materials and methods
Subjects
This study included 1,510 aﬀected research subjects
with BP. These were sampled in three cohorts. The
ﬁrst cohort, UCL1, included 506 research subjects
with bipolar I disorder (BP-I), deﬁned by the pres-
ence of mania and hospitalization according to
Research Diagnostic Criteria (RDC) (62). UCL1
was included in the previously reported mega-
analysis by the Psychiatric Genetic Consortium
(PGC) BP GWAS (17). The second and third
cohorts, UCL2 and UCL3, consisted, respectively,
of 593 and 411 subjects with BP-I or bipolar II dis-
order (BP-II). Ancestry screening was used as a
selection criterion for the inclusion of cases. Sam-
ples were included if at least three out of four
grandparents were English, Irish, Scottish, or
Welsh and if the fourth grandparent was non-Jew-
ish European, before the European Union enlarge-
ment in 2004. The sample of 1,095 controls
comprised 614 screened subjects who had no ﬁrst-
degree family or personal history of psychiatric ill-
ness and an additional 481 unscreened normal
British subjects, obtained from the European Col-
lection of Animal Cell Cultures (ECACC).
National Health Service (NHS) multicentre
research ethics approval was obtained. All partici-
pants provided signed consent.
Research subjects with BP had been given an
NHS clinical diagnosis of ICD-10 BP and then
needed to fulﬁl RDC (62) for BP with clinical
data collected by the lifetime version of the
Schizophrenia and Aﬀective Disorder Schedule
(SADS-L) (63). DNA samples were collected
from blood samples from the UCL1 cohort,
saliva samples for the UCL2 cohort, and a mix-
ture of both blood and saliva for the UCL3 sam-
ples. DNA from blood samples was extracted
using a standard phenol–chloroform method and
from saliva samples using the Oragene protocol
for DNA extraction (DNA Genotek, Ottawa,
ON, Canada).
WGS
WGS was performed on 99 of the subjects with
BP-I selected from all our cohorts who had a posi-
tive family history of BP or bipolar spectrum disor-
der and an early age at onset. The genomic DNA
was sequenced using 100 bp paired-end reads on a
Hi-Seq 1000 (Illumina Inc., San Diego, CA, USA).
Sequence data alignment to the National Center
for Biotechnology Information human reference
genome 37.1 (hg19) and variant calling was
performed using the CASAVA 1.8.2 pipeline at Illu-
mina (http://res.illumina.com/documents/products/
technotes/technote_snp_caller_sequencing.pdf). The
sequence data from these individuals were further
analysed and annotated using kGAP (Knome Inc.,
Boston, MA, USA).
Variant selection
ANK3 and CACNA1C non-synonymous variants
present in the coding exons were identiﬁed using
the Knome VARIANTS software (Knome Inc.)
(Supplementary Table 1). The same software was
used to identify variants in the 50 untranslated
region (UTR), 30UTR, splicing sites [donor site
consists of 5 bp in the exon and 6 bp in the
intron, acceptor site consist of 3 bp in the exon
and 20 bp in the intron (64)], promoter region
(1,000 bp from the ﬁrst exon of every coding
isoform), and the third intron of CACNA1C
(Supplementary Table 1, Supplementary Fig. 1,
Supplementary Fig. 2). Allele counts for each
SNP in the BP samples were compared to those
from the 372 European samples in the 1,000 Ge-
nomes (1,000G) Project (phase 1, version 3; ftp://
ftp.1000genomes.ebi.ac.uk/vol1/ftp/release/20110521/
ALL.wgs.phase1_release_v3.20101123.snps_indels_
sv.sites.vcf.gz). SNPs for which the variant allele
was more common in subjects with BP than in
the 1,000G Project data, signiﬁcant at p < 0.05
using Fisher’s exact test, were chosen for geno-
typing in the complete UCL case–control sample.
Variants which were present in poly-base regions
and insertions in repeat regions were excluded
from genotyping.
The variants in the third intron of CACNA1C
were selected if they met four criteria:
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(i) Located in the third intron of CACNA1C
between ﬂanking high recombination peaks
(chr12:2271532-2425994 hg19);
(ii) Located in a putative functional site deﬁned by
being an ENCODE-marked element (65);
(iii) Located in a conserved non-coding sequence,
determined using the mammalian conservation
track on the University of California Santa Cruz
(UCSC) genome browser (http://genome.ucsc.edu/)
or by their Genomic Evolutionary Rate Proﬁling
(GERP) scores;
(iv) Not in a repeat region.
Each variant was validated by conﬁrming the bp
call conﬁdence using individual Binary Alignment/
Map (BAM) ﬁles before genotyping. Bioinformatic
analysis to determine potentially functional SNPs
was carried out using the UCSC genome browser,
Alibaba2.1 (http://www.gene-regulation.com/pub/
programs/alibaba2/index.html), targetscan 6.2
(http://www.targetscan.org/), miRanda (http://
www.microrna.org/microrna/home.do), PolyPhen-2
(http://genetics.bwh.harvard.edu/pph2/), and Sort-
ing Intolerant From Tolerant (SIFT) (http://sift.
jcvi.org/).
Genotyping
Genotyping for the selected SNPs in 1,510 BP
cases (UCL1, UCL2, and UCL3 samples) and
1,095 ancestrally matched controls was performed
in-house with allele-speciﬁc polymerase chain reac-
tion (PCR) using KASPar reagents (KBiosciences,
Hoddesdon, UK) on a LightCycler 480 (Roche,
Burgess Hill, UK) real-time PCR machine. For all
SNPs genotyped, 17% of samples were duplicated
to detect error and conﬁrm the reproducibility of
genotypes. Allele-speciﬁc primers were designed
for each of the SNPs using Primer Picker (KBio-
sciences), as shown in Supplementary Table 2. All
these data were analysed to conﬁrm Hardy–Wein-
berg equilibrium (HWE). Allelic associations for
SNPs were performed using Fisher’s Exact test.
Signiﬁcance values shown for all analyses are
uncorrected for multiple testing, and a cutoﬀ sig-
niﬁcance value of p < 0.05 was used.
Burden analysis
A burden analysis was performed on the data sepa-
rately for ANK3 and CACNA1C. A chi-square test
was used to compare the numbers of case and con-
trol individuals carrying one or more of the variant
alleles against the numbers of case and control
individuals who were found to be homozygous for
the reference alleles at all of the loci tested.
Haplotype analysis
Haplotype analysis was performed using Haplo-
view (66) to determine the LD between GWAS-
associated SNPs and the rare variants reported
here. Haplotype blocks were determined using a
solid spine of LD (D0 = 1).
Results
Variant calling and selection
WGS in 99 samples with BP produced a mean
depth coverage of 37.0 with 90% of the genome
sequenced. A total of 0.12% of bases were hetero-
zygous and the transition/transversion (Ti/Tv)
ratio was 2.0 (see Supplementary Table 3).
Using the criteria set out above, 82 ANK3 and
43 CACNA1C variants were identiﬁed in the cod-
ing exons, 50UTR, 30UTR, splicing sites, and pro-
moter region; and a further 108 CACNA1C
variants were identiﬁed in the intron 3 region
12:2271532-2425994 (Supplementary Table 1, Sup-
plementary Fig. 1, Supplementary Fig. 2).
These variants were further ﬁltered using a cut-
oﬀ threshold of p < 0.05 using Fisher’s exact test
against the 1,000G Project (67) European allele fre-
quencies. After ﬁltering, three variants remained in
ANK3 and these comprised two known SNPs,
rs184389434 and rs139972937, and a previously
unreported SNP at position ss825679002; ten
CACNA1C variants remained after ﬁltering and
these comprised ﬁve known SNPs (rs146482058,
rs79398153, rs191953785, rs112312080, and rs113
414207) and four previously unreported variants
(ss825679004, ss825679005, ss825679006, and
ss825679007 (Table 1, Supplementary Fig. 1, Sup-
plementary Fig. 2).
The ANK3 variant rs184389434 is located in
the promoter region of the gene and was pre-
dicted to create a binding site for three new tran-
scription factors [ETS-related gene (Erg-1),
Ultrabithorax (Ubx) and Octamen-1 (Oct-1)].
rs139972937 causes a non-conservative amino
acid change from asparagine to serine at position
2,643 (N2643S) in exon 34 of the alternative iso-
forms NM_020987.3 and CCDS7258.1. The
N2643S amino acid substitution was predicted to
be benign with a score of 0 (sensitivity 1, speciﬁc-
ity 0) by PolyPhen-2 and tolerated with a score of
0.71 by SIFT. The previously unreported ANK3
variant, ss825679002, was located in the 30UTR
of the gene and was found to be in a microRNA
binding site. Bioinformatic analysis using target-
scan and miRanda predicted no eﬀect on microR-
NA binding.
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One of the novel variants in CACNA1C,
ss825679004, was in the promoter region of the
gene. Alibaba 2.1 analysis of ss825679004 pre-
dicted it to disrupt the binding sites for three tran-
scription factors [Activating Enhancer Binding
Protein-2alpha (AP-2alph), NF-muE1, Speciﬁcity
Protein-1 (Sp1)] and to create a new one for a dif-
ferent transcription factor [GC Factor (GCF)].
CACNA1C variant ss825679005 is the sixth base in
the intron of the splice donor site for exon 17. This
exon is present in all known isoforms of the gene
and this variant might alter splicing eﬃciency.
The CACNA1C intron 3 variants rs146482058,
rs79398153, rs191953785, rs112312080, rs113414
207, ss825679006, and ss825679007 were present in
the region of high LD between chr12:2,230,353
and chr12:2,559,413. Each variant was also located
in an ENCODE marked region (65). All seven
SNP regions are marked by H3 mono-methylation
of lysine 4 (H3K4me1), H3 tri-methylation of
lysine 4 (H3K4me3), and H3 acetylation of lysine
27 (H3K27ac), and active transcriptional enhanc-
ers with distinct chromatin signatures (68). Enrich-
ment for H3K4me1 and H3K27ac at a genetic
level distinguishes active enhancers from inactive
or poised enhancers (69, 70). The presence of
H3K4me1- and H3K27ac-marked chromatin, with
low levels of H3K4me3 and an absence of another
histone marker, H3K27me3, represent putative
human embryonic stem cell (hESC) enhancers and
have been shown to localize proximally to genes
that are expressed during development in hESCs
and in epiblast cells (70). Additionally,
rs112312080 and ss825679007 were found to be
present on DNAse I hypersensitivity sites, as listed
by the ENCODE project.
Genotyping
Assays were designed for 13 SNPs which passed
ﬁltering tests for genotyping in the complete UCL
BP case–control sample. Genotype data were
Table 1. Test of association with ANK3 and CACNA1C variants with bipolar disorder
Gene SNP
Location
(hg19)
Position in
gene Change
European
1,000G
MAF MLP
Number of
samples
Genotype
counts MAF
p-
valuea
ANK3 rs184389434 10: 62493837 Promoter A/T 0 1.39 BP 1,469 0/15/1454 0.0051 0.41
Control 1,031 0/12/1019 0.0058
ANK3 ss825679002 10: 61788626 30UTR C/A 0 1.39 BP 1,467 0/36/1431 0.012 0.35
Control 1,026 0/28/998 0.014
ANK3 rs139972937 10: 61832711 Exon
(N2643S)
A/G 0 1.39 BP 1,474 0/9/1465 0.0031 0.042
Control 1,030 0/1/1029 0.0005
CACNA1C ss825679004 12: 2161934 Promoter G/A 0 1.39 BP 1,467 0/5/1462 0.0017 0.57
Control 1,031 0/4/1027 0.0019
CACNA1C ss825679005 12: 2694668 Splice site G/A 0 1.39 BP 1,473 0/3/1470 0.0010 0.7
Control 1,032 0/2/1030 0.0010
CACNA1C rs146482058 12: 2403077 Intronb,e –/T 0 10.9 BP 1,486 3/134/1322 0.048 0.31
Control 1,022 4/96/922 0.051
CACNA1C rs79398153 12: 2295156 Intronb,e C/T 0.01 1.57 BP 1,498 3/88/1380 0.032 0.015
Control 1,029 0/44/985 0.021
CACNA1C rs191953785 12: 2425097 Intronb,e C/T 0 2.29 BP 1,475 0/25/1450 0.0085 0.34
Control 1,020 0/20/1005 0.0098
CACNA1C rs112312080 12: 2354510 Intronb,c,e C/T 0.001 2.02 BP 1,501 0/35/1439 0.012 0.30
Control 1,028 0/20/1008 0.0097
CACNA1C rs113414207 12: 2292742-
2292743
Intronb,d,e –/C 0 2.15 BP 1,497 0/76/1394 0.026 0.19
Control 1,026 0/44/982 0.021
CACNA1C ss825679006 12: 2329069 Intronb,d,e G/T 0 2.15 BP 1,498 0/14/1457 0.0048 0.43
Control 1,033 0/8/1024 0.0039
CACNA1C ss825679007 12: 2423175 Intronb,c,d,e G/C 0 2.15 BP 1,502 0/4/1471 0.0014 0.34
Control 1,026 0/1/1025 0.0010
1,000G = 1,000 Genomes; ANK3 = ankyrin 3; BP = bipolar disorder; CACNA1C = L-type calcium channel a1C subunit; MAF = minor
allele frequency; SNP = single nucleotide polymorphism; UTR = untranslated region; European 1,000G MAF = MAF for European sam-
ples in the 1,000G Project (72); MLP = minus log10 of Fisher’s exact p-value comparing UCL whole-genome sequence allele frequency
to the European 1,000G MAF.
ap-significance value for a Fisher’s exact test.
bH3K4Me1, H3K4Me3, and H3K27Ac marks.
cDNAse hypersensitivity cluster marks.
dHuman mRNA.
eConserved region. The distributions of genotype data for all SNPs were in Hardy–Weinberg equilibrium in the cases and controls.
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generated for 12 of these variants and the genotype
distributions for each SNP followed HWE in the
case and control cohorts. The non-synonymous
ANK3 variant rs139972937 was found to be associ-
ated with BP (Fisher’s exact test p = 0.042)
(Table 1). Nine cases with BP and only one control
were found to be heterozygous for this variant.
None of the other ANK3 variants were found to be
associated with BP, as shown in Table 1.
Of the SNPs found in the CACNA1C intronic
region, rs79398153 was found to be associated with
BP (Fisher’s exact test p = 0.015). We detected 88
heterozygote and three homozygote cases for this
variant and 44 heterozygote controls. The excess of
homozygotes may possibly represent a recessive
eﬀect, as only one homozygote would be expected
under HWE, but this excess is not statistically
signiﬁcant (71). rs79398153 is located in an
ENCODE-marked region for H3K4me1,
H3K27ac, and H3Kme3. None of the other intron-
ic CACNA1C SNPs were associated with BP.
Imputation for rs79398153 in UCL1 using GWAS
data showed that it was still signiﬁcantly associated
with BP (p = 0.022) (17). Burden analysis showed
that, overall, there was no excess of the variants
genotyped in cases versus controls for either CAC-
NA1C or ANK3.
Haplotype and LD analysis at ANK3 and CAC-
NA1C was performed separately in Haploview (66)
to examine the co-occurrence of the BP GWAS
SNP alleles [ANK3 rs10994285, rs2018783,
rs10994336, rs10994397, rs10821792, rs1938526
(14, 26, 32–34); CACNA1C rs1006737 (14);
rs4765913 (14); rs476590 (31); and rs4765914 (20)]
with the BP risk variant alleles (rs139972937, allele
G; rs79398153, allele T). For both sets of analyses,
the BP risk variant alleles reported here were found
to be associated with the GWAS SNP alleles that
were more common in the control subjects. Thus,
these variants could not be accounting for the
GWAS signals. The results of the LD analysis are
shown in Table 2.
Discussion
We have analysed genetic variation by WGS in
two of the best-replicated bipolar susceptibility
genes, CACNA1C and ANK3. This analysis has
identiﬁed novel possible BP susceptibility variants
in both of these genes. The CACNA1C intron 3
variant rs79398153 may impact CACNA1C gene
expression by virtue of its presence in an
ENCODE-marked transcriptional enhancer
region.
The ANK3 amino acid changing variant,
rs139972937 (N2643S), was associated with BP in
our sample (p = 0.042). This rare variant was also
found in two of 1,119 cases and one of 1,078 con-
trols and in a family containing seven subjects with
BP, a father and six oﬀspring, where only the
father and two of the oﬀspring possessed the vari-
ant (44). These conﬂicting ﬁndings are not uncom-
mon in the genetics of complex diseases but this
lack of support casts doubt on the true aetiological
importance of this variant in BP.
It is of note that the allele frequencies of some
of the variants selected for genotyping were found
to be markedly diﬀerent in our control samples
compared to the frequencies in the European
1,000G Project. This underlies the importance of
typing variants in matched control samples on
the same platform rather than relying on publi-
cally available data such as the 1,000G Project in
order to mitigate possible spurious association
ﬁndings.
The variants we have found appear to be acting
independently of the allelic and haplotypic associa-
tions found in the previous BP allelic association
studies. Independent genetic replication and bio-
logical validation of intronic potential aetiological
bp changes would support the argument for carry-
ing out WGS as well as exome sequencing in BP.
The biphasic nature of BP makes a compelling
argument for the existence of genetically deter-
mined pathological switch mechanisms that may
manifest themselves in the loss of control of gene
expression. Findings such as ours may help to
explain the ‘missing heritability’ in this common
complex disorder. Further analyses in much larger
samples are needed to ﬁnd aetiological bp changes
in the ANK3 and CACNA1C genes that are carried
by the main haplotypes showing strong association
with BP. The outcome could be personalized treat-
ment for BP, based on susceptibility genotypes.
Table 2. Pairwise linkage disequilibrium analysis between bipolar dis-
order-associated SNPs reported here and previous GWAS SNPs
Gene Marker 1 Marker 2 D0 r2 LOD
ANK3 rs139972937 rs10994285 1 0 0.17
ANK3 rs139972937 rs2018783 1 0.002 0.51
ANK3 rs139972937 rs10994336 1 0 0.03
ANK3 rs139972937 rs10994397 1 0 0.03
ANK3 rs139972937 rs10821792 1 0 0.21
ANK3 rs139972937 rs1938526 1 0 0.26
CACNA1C rs79398153 rs1006737 0.754 0.016 1.06
CACNA1C rs79398153 rs1024582 0.729 0.014 0.87
CACNA1C rs79398153 rs4765913 0.822 0.029 2.12
CACNA1C rs79398153 rs4765914 0.829 0.032 2.31
ANK3 = ankyrin; CACNA1C = L-type calcium channel a1C sub-
unit; GWAS = genome-wide association studies; LOD = loga-
rithm of the odds; SNPs = single nucleotide polymorphisms.
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Supporting Information
Additional Supporting Information may be found in the online
version of this article:
Figure S1. The introns and exons of the diﬀerent splice variants
of the ANK3 gene are shown, along with the genomic regions
of the gene that were analysed for variant selection. The loca-
tions of the variants detected by sequencing are shown, as are
the variants that were selected for genotyping in the full case
control sample.
Figure S2. The introns and exons of the diﬀerent splice variants
of the CACNA1C gene are shown, along with the genomic
regions of the gene that were analysed for variant selection.
The locations of the variants detected by sequencing are
shown, as are the variants that were selected for genotyping in
the full case–control sample.
Table S1. Variants identiﬁed using the Knome VARIANTS
software (Knome). VAF = variant allele(s) frequency.
Table S2. Allele-speciﬁc primers designed using Primer Picker
(KBiosciences) for genotyping.
Table S3. Next Generation Sequencing Control information.
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